Gennova Biopharmaceuticals Limited, a subsidiary of Emcure Pharmaceuticals, on Tuesday said it has signed a new agreement with the Coalition for Epidemic Preparedness Innovations (CEPI ...

Tissue Plasminogen Activator Market is estimated to be valued at US$ 2.58 Bn in 2023, and is expected to exhibit a CAGR of 5.2% by (2023-2030). BURLINGAME, CA, UNITED STATES, January 15, 2025 ...

Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update. Paradigm Biopharmaceuticals Ltd has submitted a revised protocol for their Phase 3 clinical trial to the US FDA, marking a ...

Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update. Paradigm Biopharmaceuticals Ltd. announced a significant change in the shareholdings of Director Paul Rennie, who now holds a ...

Indian generic drugmaker Emcure Pharmaceuticals and U.S. vaccine developer HDT Bio have settled allegations that Emcure stole HDT trade secrets during their joint work on a COVID-19 shot, the ...

Emcure Pharmaceuticals Ltd and its arm Gennova Biopharmaceuticals have settled all legal disputes with HDT Bio Corp and have signed a long-term agreement to develop mRNA vaccines, the company said ...

Gennova Biopharmaceuticals Ltd., a company involved in the business of research and development, manufacturing and abroad of biotechnology-based products, announces the launch of the India’s first ...

Gennova Biopharmaceuticals has launched a paediatric packsize of pegaspargase, used to treat an orphan disease like Acute Lymphoblastic Leukaemia (ALL), a rare and challenging form of blood cancer ...

The positions in the table below reflect the Gennova Biopharmaceuticals Limited's position overall, domestically, within their sector, and in various subject areas based on their Share.

Oslo: The Coalition for Epidemic Preparedness Innovations (CEPI) and Pune-based Gennova Biopharmaceuticals Ltd announced a new funding agreement to advance the development of their self-amplifying ...